KA Hommel et al. JPGN 2024; 78:1273–1278. Pilot and feasibility of the SMART IBD mobile app to improve self-management in pediatric inflammatory bowel disease
The Self‐Management Assistance with Recommended Treatment (SMART) IBD app –Key findings:
- Patients rated the app quality as good and accessed the app adequately overall, with some pages being used often.
- Medication adherence increased over the course of the study and was associated with sleep duration, mood, and stool consistency and blood content.
My take: IBD Management apps could be quite helpful, especially for teens and young adults.
S Hsiang et al. Inflammatory Bowel Diseases, Volume 30, Issue 8, August 2024, Pages 1284–1294, https://doi.org/10.1093/ibd/izad166. Safety, Effectiveness, and Treatment Persistence of Subcutaneous Vedolizumab in IBD: A Multicenter Study From the United Kingdom
Methods: IBD patients (n=563) on IV vedolizumab across 11 UK sites agreed to transition to SC injections or otherwise continued IV treatment
Key findings:
- Data from 563 patients, demonstrated no differences in disease activity, remission rates, and quality of life between the SC and IV groups at all time points
- Drug persistence at week 52 was similar (81.1% vs 81.2%; P = .98)
Related blog posts:
- SC Infliximab versus Vedolizumab for Crohn’s Disease and for Ulcerative Colitis
- Vedolizumab and Infliximab: Expected Dosing When Switching From IV to SC Routes
CFD Li Wai Suen, et al. Inflammatory Bowel Diseases, Volume 30, Issue 8, August 2024, Pages 1389–1405, https://doi.org/10.1093/ibd/izad183. Factors Associated With Response to Rescue Therapy in Acute Severe Ulcerative Colitis
This systematic review identified 101 completed studies were eligible for inclusion.
Related blog posts:
- Dr. Joel Rosh: Positioning Therapies for Pediatric Ulcerative Colitis
- IBD Brief Updates: Anti-TNF Loss of Response, Upadacitinib for ASUC, Risk Factors for Developing IBD
- Bridge Therapy for Ustekinumab with Acute Severe Ulcerative Colitis
- ARCH Study: Higher Doses of Infliximab in Acute Severe Ulcerative Colitis
- Upadacitinib vs Ustekinumab for Ulcerative Colitis
- Giving Tacrolimus Another Look for Severe Colitis
- Treatments for “Bad” Inflammatory Bowel Disease (Part 2) & Reassuring Data on Tofacitinib
- Early Assessment of Acute Ulcerative Colitis with ACE (Albumin, CRP, & Endoscopy)
gutsandgrowth 